as I understand it.....it was a investigator initiated trial, that was allowed to occur based on phase 3 results of remestemcel-L to investigate extending the application from acute treatments to also include chronic treatments.
so I have no idea what phase level that is...not even going to pretend I do.
but "post-phase3", as I think they get a free pass as part of the extended access process?
i'm probably wrong, as don't have a full grasp ( and no way have I ever claimed to be a expert) ….but to me sounds promising to be alread exploring and having good results with extended applications.
@Doug Diamond if they could merge their success with CYP's manufacturing process.... would be a behemoth of a company then...be scary the end results...
as I understand it.....it was a investigator initiated trial,...
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
0.005(2.13%) |
Mkt cap ! $43.11M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.0¢ | 23.5¢ | $14.74K | 61.89K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4000 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 96221 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
24.0¢ |
Change
0.005 ( 2.13 %) |
||||
| Open | High | Low | Volume | ||
| 23.5¢ | 24.0¢ | 23.5¢ | 6875 | ||
| Last updated 10.47am 03/05/2024 ? | |||||
| CYP (ASX) Chart |